{"id":3896,"date":"2025-04-22T11:13:28","date_gmt":"2025-04-22T11:13:28","guid":{"rendered":"http:\/\/studies.nefro-nl.nl\/?page_id=3896"},"modified":"2026-10-16T15:07:05","modified_gmt":"2026-10-16T15:07:05","slug":"studies","status":"publish","type":"page","link":"https:\/\/studies.nefro-nl.nl\/en\/studies\/","title":{"rendered":"Studies"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"3896\" class=\"elementor elementor-3896\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-0c7666f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"0c7666f\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;shape_divider_top&quot;:&quot;curve&quot;}\">\n\t\t\t\t\t<div class=\"elementor-shape elementor-shape-top\" aria-hidden=\"true\" data-negative=\"false\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 1000 100\" preserveAspectRatio=\"none\">\n    <path class=\"elementor-shape-fill\" d=\"M1000,4.3V0H0v4.3C0.9,23.1,126.7,99.2,500,100S1000,22.7,1000,4.3z\"\/>\n<\/svg>\t\t<\/div>\n\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-extended\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6521588\" data-id=\"6521588\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c5cf1a9 elementor-widget elementor-widget-heading\" data-id=\"c5cf1a9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Recruiting Studies<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a3d20be elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"a3d20be\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-extended\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4e5bd3d\" data-id=\"4e5bd3d\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a32f583 elementor-widget elementor-widget-text-editor\" data-id=\"a32f583\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><strong>Baxduo-PACIFIC<\/strong><\/h3>\n<h4><strong>Baxduo-PACIFIC: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific)<\/strong><\/h4>\n<b>More information:<\/b>\u00a0<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06742723\" target=\"_blank\" rel=\"noopener\">clinicaltrials.gov<\/a>\n\n<strong>Investigational product<\/strong>: Baxdrostat\n\n<strong>Population<\/strong>:\n<p style=\"font-weight: 400;\">eGFR \u226530 and &lt;60 mL\/min\/1.73 m2 with UACR between 3.39 mg\/mmol and 56.5 mg\/mmol, or\neGFR \u226530 and \u226475 mL\/min\/1.73 m2 with UACR between 56.5 mg\/mmol and \u2264565 mg\/mmol or UPCR between 79 mg\/mmol and 790 mg\/mmol<\/p>\n<strong>Phase<\/strong>: III\n\n<strong>Starting year<\/strong>: 2025\n\n<b>Participating sites:<\/b>\u00a0Albert Schweitzer hospital (Dordrecht), Amsterdam UMC, Isala (Zwolle), LUMC (Leiden), Meander Medisch Centrum (Amersfoort), MUMC+ (Maastricht), St. Antonius (Nieuwegein), Tergooi MC (Hilversum), UMCG (Groningen)\n\n<strong>National lead<\/strong>: prof.dr. M.H. de Borst (UMCG)\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d368430 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"d368430\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4812c67 elementor-widget elementor-widget-text-editor\" data-id=\"4812c67\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><strong>PROMISE<\/strong><\/h3><h4><strong>PROMISE: Potassium correction for RAAS optimization in chronic kidney disease<\/strong><\/h4><p><b>More information:<\/b>\u00a0<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06256991\" target=\"_blank\" rel=\"noopener\">clinicaltrials.gov<\/a><\/p><p><strong>Investigational product<\/strong>: Patiromer<\/p><p><strong>Population<\/strong>: Stage 3b-4 CKD with ACR &gt;3 mg\/mmol<\/p><p><strong>Phase<\/strong>: IV<\/p><p><strong>Starting year<\/strong>: 2024<\/p><p><b>Participating sites:<\/b>\u00a0Amsterdam UMC, Frisius MC (Leeuwarden), Isala (Zwolle), UMCG (Groningen)<\/p><p><strong>National lead<\/strong>: prof.dr. M.H. de Borst (UMCG)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cf29aea elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"cf29aea\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-90ae992 elementor-widget elementor-widget-text-editor\" data-id=\"90ae992\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><b>PODOMOUNT-pFSGS<\/b><\/h3>\n<h4><b>PODOMOUNT-pFSGS, a Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants<\/b><\/h4>\n<p><b>More information:<\/b>&nbsp;<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07220083\" target=\"_blank\" rel=\"noopener\">clinicaltrials.gov<\/a><\/p>\n<p><strong>Investigational product<\/strong>: BI 764198 (TRPC6 inhibitor)<\/p>\n<p><strong>Population<\/strong>: Patients aged \u226512 years with biopsy-proven primary FSGS or genetic FSGS caused by a TRPC6 mutation, UPCR \u22651500 mg\/g and eGFR \u226525 mL\/min\/1.73 m\u00b2.<\/p>\n<p><strong>Phase<\/strong>: III<\/p>\n<p><strong>Starting year<\/strong>: 2026<\/p>\n<p><b>Participating sites:<\/b> UMC Groningen (actively recruiting), Amsterdam UMC (pending activation)<\/p>\n<p><b><i>Referral note:<\/i><\/b><i> Due to limited recruitment timelines, referral of potentially eligible patients from non-participating centres is encouraged. Patients can be referred to the participating sites for screening and potential inclusion.<\/i><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2582a4b elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"2582a4b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6b9d619 elementor-widget elementor-widget-text-editor\" data-id=\"6b9d619\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><b>PODOMOUNT-Basket<\/b><\/h3>\n<h4><b>PODOMOUNT-Basket, a Phase II, Multicentre, Randomised, 2-arm Parallel-group, Double-blind, Placebo-controlled Basket Trial to Assess Safety, Tolerability, PK, and Efficacy of BI 764198 in Four Proteinuric Kidney Diseases<\/b><\/h4>\n<p><b>More information:<\/b>&nbsp;<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07355296\" target=\"_blank\" rel=\"noopener\">clinicaltrials.gov<\/a><\/p>\n<p><strong>Investigational product<\/strong>: BI 764198 (TRPC6 inhibitor)<\/p>\n<p><strong>Population<\/strong>: Male or female participants \u226518 years old (\u226512 years old for TR-pMCD and Alport Syndrome excluding the EU) with one of the following proteinuric kidney diseases:<\/p>\n<ul>\n<li>maladaptive secondary FSGS<\/li>\n<li>treatment-resistant primary minimal change disease (MCD)<\/li>\n<li>Alport syndrome<\/li>\n<li>treatment-resistant primary membranous nephropathy (MN)<\/li>\n<\/ul>\n<p>with eGFR \u226525 mL\/min\/1.73 m\u00b2 and persistent proteinuria despite standard of care.<br><strong>Phase<\/strong>: II<\/p>\n<p><strong>Starting year<\/strong>: 2026<\/p>\n<p><b>Participating sites:<\/b> UMC Groningen (actively recruiting), Amsterdam UMC (pending activation)<\/p>\n<p><b><i>Referral note:<\/i><\/b><i> Due to limited recruitment timelines, referral of potentially eligible patients from non-participating centres is encouraged. Patients can be referred to the participating sites for screening and potential inclusion.<\/i><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7b15e2a elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7b15e2a\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;shape_divider_top&quot;:&quot;curve&quot;}\">\n\t\t\t\t\t<div class=\"elementor-shape elementor-shape-top\" aria-hidden=\"true\" data-negative=\"false\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 1000 100\" preserveAspectRatio=\"none\">\n    <path class=\"elementor-shape-fill\" d=\"M1000,4.3V0H0v4.3C0.9,23.1,126.7,99.2,500,100S1000,22.7,1000,4.3z\"\/>\n<\/svg>\t\t<\/div>\n\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-extended\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3ea655a\" data-id=\"3ea655a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-53618a4 elementor-widget elementor-widget-heading\" data-id=\"53618a4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Follow-up Studies<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-42926c0 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"42926c0\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-extended\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-484ca61\" data-id=\"484ca61\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-b9bb4fa elementor-widget elementor-widget-text-editor\" data-id=\"b9bb4fa\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><strong>K+ in CKD trial<\/strong><\/h3><h4><strong>K+ in CKD trial<\/strong><\/h4><p><b>More information:<\/b>\u00a0<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03253172\" target=\"_blank\" rel=\"noopener\">clinicaltrials.gov<\/a><\/p><p><strong>Investigational product<\/strong>: Potassium chloride \/ potassium citrate<\/p><p><strong>Population<\/strong>: Stage 3b-4 CKD with ACR &gt;3 mg\/mmol<\/p><p><strong>Phase<\/strong>: III<\/p><p><strong>Starting year<\/strong>: 2017<\/p><p><strong>National lead<\/strong>: prof.dr. E.J. Hoorn (Erasmus MC)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-4b22c0b elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"4b22c0b\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;shape_divider_top&quot;:&quot;curve&quot;,&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"elementor-shape elementor-shape-top\" aria-hidden=\"true\" data-negative=\"false\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 1000 100\" preserveAspectRatio=\"none\">\n    <path class=\"elementor-shape-fill\" d=\"M1000,4.3V0H0v4.3C0.9,23.1,126.7,99.2,500,100S1000,22.7,1000,4.3z\"\/>\n<\/svg>\t\t<\/div>\n\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-extended\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f1ce5a7\" data-id=\"f1ce5a7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2a71ea4 elementor-widget elementor-widget-heading\" data-id=\"2a71ea4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<p class=\"elementor-heading-title elementor-size-default\">Contact NEFRO-NL<\/p>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-71d8d59 elementor-widget elementor-widget-heading\" data-id=\"71d8d59\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">How can we help?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-29f6222 kc_text_block elementor-widget elementor-widget-text-editor\" data-id=\"29f6222\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Would you like to know more about NEFRO-NL, our research network or our services? Our project managers will be happy to help. Contact us at <a href=\"mailto:info@nefro-nl.nl\"><strong>info@nefro-nl.nl<\/strong><\/a>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5dcd480 e-grid nefro-card-row e-con-boxed e-con e-parent\" data-id=\"5dcd480\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2450d38 e-con-full nefro-card e-flex e-con e-child\" data-id=\"2450d38\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cd043f5 elementor-widget elementor-widget-image\" data-id=\"cd043f5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/studies.nefro-nl.nl\/wp-content\/uploads\/2025\/10\/A.-de-Boer-2.png\" title=\"Antina de Boer | NEFRO-NL\" alt=\"antina-de-boer-nefro-nl.jpg\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5ce47ee elementor-widget elementor-widget-heading\" data-id=\"5ce47ee\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Antina de Boer<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-20d06c3 elementor-widget elementor-widget-heading\" data-id=\"20d06c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">project manager<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-9125509 e-con-full nefro-card e-flex e-con e-child\" data-id=\"9125509\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8e6ad1e elementor-widget elementor-widget-image\" data-id=\"8e6ad1e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/studies.nefro-nl.nl\/wp-content\/uploads\/2026\/10\/heleen-van-den-heuvel-nefro-nl-2.jpg\" title=\"Heleen van den Heuvel | NEFRO-NL\" alt=\"Portrait of Heleen van den Heuvel\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cf52705 elementor-widget elementor-widget-heading\" data-id=\"cf52705\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Heleen van den Heuvel<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2826bea elementor-widget elementor-widget-heading\" data-id=\"2826bea\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">project manager<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Recruiting Studies Baxduo-PACIFIC Baxduo-PACIFIC: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific) More information:\u00a0clinicaltrials.gov Investigational product: Baxdrostat Population: eGFR \u226530 and &lt;60 mL\/min\/1.73 m2 with UACR between 3.39 mg\/mmol and 56.5 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3896","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/studies.nefro-nl.nl\/en\/wp-json\/wp\/v2\/pages\/3896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studies.nefro-nl.nl\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/studies.nefro-nl.nl\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/studies.nefro-nl.nl\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/studies.nefro-nl.nl\/en\/wp-json\/wp\/v2\/comments?post=3896"}],"version-history":[{"count":55,"href":"https:\/\/studies.nefro-nl.nl\/en\/wp-json\/wp\/v2\/pages\/3896\/revisions"}],"predecessor-version":[{"id":5847,"href":"https:\/\/studies.nefro-nl.nl\/en\/wp-json\/wp\/v2\/pages\/3896\/revisions\/5847"}],"wp:attachment":[{"href":"https:\/\/studies.nefro-nl.nl\/en\/wp-json\/wp\/v2\/media?parent=3896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}